Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma

Cancer Research

Volumn 62, Issue 18, 2002, Pages 5242-5247

  Jänne, Pasi A ^a   Taffaro, Michele L ^a   Salgia, Ravi ^a   Johnson, Bruce E ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; AGAROSE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B; PROTEIN P27;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; GROWTH INHIBITION; HUMAN; HUMAN CELL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; WOUND HEALING;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL DIVISION; EPIDERMAL GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; PHOSPHORYLATION; PLEURAL NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0037105665     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial
2. Surgically debulked malignant pleural mesothelioma: Results and prognostic factors
3. Current therapy for mesothelioma
4. Malignant pleural mesothelioma
5. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients
6. A Phase II study of gemcitabine in patients with malignant pleural mesothelioma
7. Gemcitabine for malignant mesothelioma: A phase II trial by the cancer and leukemia group B
8. Etoposide in malignant pleural mesothelioma: Two Phase 11 trials of the EORTC Lung Cancer Cooperative Group
9. Chemotherapy for malignant mesothelioma
10. Epidermal growth factor receptor and HER2- neu mRNA expression in non-small cell lung cancer is correlated with survival
11. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival
12. Expression of growth factors and their receptors in human early colorectal carcinomas: Immuno-histochemical study
13. Human breast cancer: Prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features
14. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor
15. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells
16. Epidermal growth factor receptor-mediated cell motility: Phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement
17. Cell movement elicited by epidermal growth factor receptor requires kinase and autophosphorylation but is separable from mitogenesis
18. The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients
19. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor α is frequent in resectable non-small cell lung cancer but does not predict tumor progression
20. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
21. Activated extracellular signal-regulated kinases: Association with epidermal growth factor receptor/transforming growth factor α expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments
22. Phase I pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
23. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer
24. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck
25. KIP1 independent of MAPK activity
26. 1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody
27. 1 arrest in prostatic cancer cell line DU145
28. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin-embedded tissue and the F4 monoclonal antibody
29. Autocrine stimulation of a human lung mesothelioma cell line is mediated through the transforming growth factor α/epidermal growth factor receptor mitogenic pathway
30. Characteristics of nine newly derived mesothelioma cell lines
31. Asbestos: Scientific developments and implications for public policy
32. Autocrine growth stimulation by transforming growth factor α in asbestos-transformed rat mesothelial cells
33. Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor
34. Increased expression of epidermal growth factor receptor in rat pleural mesothelial cells correlates with carcinogenicity of mineral fibres
35. Characterization of the state of differentiation of six newly established human non-small-cell lung cancer cell lines
36. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling
37. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines
38. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
39. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coad-ministration of ZD1839 (Iressa). An inhibitor of EGFR tyrosine kinase
40. Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 ("Iressa"), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)
41. Phase II study of vinorelbine in patients with malignant pleural mesothelioma
42. Prevention of tumour seeding following thoracoscopy in mesothelioma by prophylactic radiotherapy
43. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy
44. Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization
45. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis